Precision Epigenomics Named an AZBio Fast Lane Company

Posted on Sun/6/SeptemberSun/6/September by AZBio

Detecting Cancer Before It Starts: How One Arizona Startup Is Transforming Precision Oncology

In modern medicine, early cancer detection remains a central goal. Identifying a tumor before symptoms emerge often makes the difference between routine intervention and a terminal diagnosis.

Standing at the leading edge of this shift is Precision Epigenomics, a Tucson-based bioscience startup whose rapid trajectory over the past 18 months is drawing national attention. Through cutting-edge liquid biopsy technology, rigorous laboratory standards, and high-impact strategic partnerships, the company is turning complex epigenetic science into life-saving clinical tools.Continue reading→

Evidence Matters: Navigating the 2026–2027 Respiratory Virus Season

Posted on Sat/5/SeptemberSat/5/September by AZBio

As Arizona enters another respiratory virus season, physicians will once again navigate patient questions surrounding influenza, SARS-CoV-2, and respiratory syncytial virus (RSV) immunization. In an environment of evolving recommendations and competing information, access to rigorous, transparent evidence is essential to informed clinical decision-making.Continue reading→

C-Path Mourns the Passing of Board Member Peter Barton Hutt

Posted on Thu/3/SeptemberThu/3/September by Roxan Olivas

TUCSON, Ariz., September 3, 2026 — Critical Path Institute® (C-Path) is deeply saddened to announce the passing of Peter Barton Hutt, a longtime member of C-Path’s Board of Directors, on September 2, 2026.Continue reading→

AZBio offers ASU tuition scholarships to Member employees and dependents

Posted on Tue/1/SeptemberTue/1/September by AZBio

Employees of AZBio Member Companies and their dependents can now get a 15% scholarship for over 400 undergraduate degrees, graduate degrees, and certificates offered by ASU Online.

Learn more at AZBio.org/InStride Continue reading→

Bright Path Labs Moves into the Fast Lane

Posted on Sun/30/AugustTue/1/September by AZBio

Bright Path is Transforming America’s Access to Essential Medicines..

Bright Path will be honored with an AZBio Fast Lane Award on Oct. 7, 2026 at the Phoenix Convention Center at the 23 annual AZBio Awards.Continue reading→

Mayor Gallego Celebrates Flinn Foundation’s Legacy of Leadership and Philanthropy

Posted on Thu/27/AugustThu/27/August by AZBio

Global Philanthropy Leadership Award recognizes an enduring commitment to strengthening Arizona and investing in its futureContinue reading→

ALIS Acquires Ella® and elbi® Technologies, Expanding AI-Powered Dementia and Behavioral Care Support for Senior Living

Posted on Wed/26/AugustWed/26/August by AZBio

Acquisition puts a dementia expert in every caregiver’s pocket to help reduce high-risk behavioral incidents and reliance on psychotropic medicationsContinue reading→

AZBioPEERS: Public Policy for the Health Innovation Founder

Posted on Tue/25/AugustTue/25/August by AZBio

Public policy decisions can directly influence how health innovations are funded, regulated, reimbursed, adopted, and accessed by patients. This AZBioPEERS video features a discussion hosted by Joan Koerber-Walker, AZBio CEO, with Steve Potts, CEO of Breakthru Medicine, and Tom Eisiminger, Jr., President and CEO of Regenesis Medical, on why policy engagement matters for health innovation entrepreneurs. Panelists will share perspectives on how founders and CEOs can stay informed, build relationships, and make their voices heard on issues that affect company growth, patient access, and Arizona’s broader life science ecosystemContinue reading→

Critical Path for Parkinson’s Announces Milestone Publication Highlighting FDA Support for Novel Biomarker to Advance Precision Medicine Strategies

Posted on Tue/25/AugustTue/25/August by Roxan Olivas

Journal of Parkinson’s Disease recognizes a decade of collaborative progress culminating in regulatory endorsement for biomarkers to enable early interventionContinue reading→

Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care

Posted on Mon/24/AugustSun/30/August by AZBio

First and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings
The test delivers consistency across clinical settings by using the same validated cutoffs in primary and specialty care
Designed for broad implementation across Roche’s installed base of more than 4,500 cobas laboratory instruments in the U.S. supporting access through existing laboratory infrastructureContinue reading→